Work

Ee251 Cost-savings Associated With Venetoclax-obinutuzumab Versus Covalent Bruton’s Tyrosine Kinase Inhibitor in Frontline Chronic Lymphocytic Leukemia: a Real-world Study

Year: 2026

Type: conference-abstract

Source: Value in Health

DOI: 10.1016/j.jval.2026.03.545

Authors: Alan P. Skarbnik, Nnadozie Emechebe, Bita Fakhri, Samin Houshyar, Beenish S. Manzoor, Nilanjan Ghosh, Mazyar Shadman, Godwin Okoye, Sophia S. Li, Paul M. Barr

Institutions: Novant Health, AbbVie (United States), Stanford Cancer Institute, Stanford University, University of Rochester Medicine, University of Rochester, Levine Cancer Institute, Fred Hutch Cancer Center, Genentech

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7166160721

Cites:

Cited by:

Related to: 10